IDNA holdings and overlap
iShares Genomics Immunology and Healthcare ETF (IDNA) holds 47 positions in its iShares file of 2026-10-27. Its three largest are Moderna (MRNA) at 12.22%, Twist Bioscience (TWST) at 6.44% and Genmab (GMAB.DK) at 5.05%, and its ten largest make up 49.9% of the fund.
In its iShares file of 2026-10-27, IDNA is 95.3% health care by sector (no sector found for 4.5%), with none of it in mega-cap tech or in the ten largest US companies by market value. By country, 66.7% of IDNA is in the United States, 6.2% in Germany, 5.6% in France and 5.2% in Japan.
What does IDNA hold, as of its issuer file of 2026-10-27?
Moderna is 12.22% of IDNA on its own, against a median largest position of 8.6% across the 28 Health Care funds with a page here. The position IDNA carries furthest above that group is Twist Bioscience at 6.44% of the fund, a company the median fund in that group does not hold at all.
| Rank | Company | Weight | Weight bar |
|---|---|---|---|
| 1 | MRNA Moderna | 12.22% | |
| 2 | TWST Twist Bioscience | 6.44% | |
| 3 | GMAB.DK Genmab | 5.05% | |
| 4 | IOVA Iovance Biotherapeutics | 4.95% | |
| 5 | 4502.JP Takeda Pharmaceutical | 3.67% | |
| 6 | CAI Caris Life Sciences | 3.61% | |
| 7 | REGN Regeneron Pharmaceuticals | 3.58% | |
| 8 | RVMD Revolution Medicines | 3.48% | |
| 9 | EXEL Exelixis | 3.45% | |
| 10 | BAYN.DE Bayer AG | 3.43% | |
| 11 | MRK Merck | 3.27% | |
| 12 | ROP.CH Roche PS Par AG | 3.26% | |
| 13 | VRTX Vertex Pharmaceuticals | 3.25% | |
| 14 | INCY Incyte | 3.17% | |
| 15 | IBRX Immunitybio | 2.84% | |
| 16 | BNTX Biontech SE ADR | 2.76% | |
| 17 | GSK.GB Glaxosmithkline | 2.75% | |
| 18 | ABCL AbCellera Biologics | 2.63% | |
| 19 | IPN.FR Ipsen SA | 2.6% | |
| 20 | SAN.FR Sanofi SA | 2.59% | |
| 21 | IDYA IDEAYA Biosciences | 2.43% | |
| 22 | 4528.JP Ono Pharmaceutical | 1.54% | |
| 23 | NVAX Novavax | 1.37% | |
| 24 | VIR Vir Biotechnology | 1.35% | |
| 25 | RCUS Arcus Biosciences | 1.33% | |
| 26 | CRSP CRISPR Therapeutics AG | 1.29% | |
| 27 | NUVB Nuvation Bio | 0.99% | |
| 28 | JANX Janux Therapeutics | 0.87% | |
| 29 | PSNL Personalis | 0.87% | |
| 30 | RIGL Rigel Pharmaceuticals | 0.79% | |
| 31 | KURA Kura Oncology | 0.74% | |
| 32 | 6887.HK Sunshine Lake Pharma Ltd | 0.74% | |
| 33 | VSTM Verastem | 0.73% | |
| 34 | PACB Pacific Biosciences of California | 0.61% | |
| 35 | XNCR Xencor | 0.59% | |
| 36 | 2595.HK Genfleet Therapeutics (Shanghai) I | 0.59% | |
| 37 | CRVS Corvus Pharmaceuticals | 0.58% | |
| 38 | ALVO Alvotech | 0.47% | |
| 39 | DNA Ginkgo Bioworks | 0.46% | |
| 40 | NTLA Intellia Therapeutics | 0.45% | |
| 41 | VLA.FR Valneva | 0.39% | |
| 42 | DSGN Design Therapeutics | 0.35% | |
| 43 | CTMX CytomX Therapeutics | 0.35% | |
| 44 | 2696.HK Shanghai Henlius Biotech H | 0.35% | |
| 45 | 174900.KR Abclon Inc | 0.22% | |
| 46 | OCGN Ocugen | 0.22% | |
| 47 | PRME Prime Medicine | 0.11% |
The most recent file iShares has published for IDNA is dated 2026-10-27, 1 day before these prices, which is the median for the iShares ETFs covered here. Every one of the 47 positions IDNA holds, with its weight, is in the fund's JSON file. See the other 80 ETFs with a page here that hold MRNA, and how their weights compare with the 12.22% IDNA gives it.
Category: Health Care, set by TickerInside from the ETF's own latest file. In its file of 2026-10-27, 100% of its stocks whose sector is known are health care companies, each in the sector the site gives that company. How categories are set.
https://tickerinside.com/api/v1/fund/idna.jsonhttps://tickerinside.com/api/v1/fund/idna.csv=IMPORTDATA("https://tickerinside.com/api/v1/fund/idna.csv")If your sheet uses a decimal comma: =IMPORTDATA("https://tickerinside.com/api/v1/fund/idna.csv"; ","; "en_US")curl -s https://tickerinside.com/api/v1/fund/idna.jsonHow much money went into or out of IDNA?
On the close of Friday, October 23, 2026, IDNA neither created nor redeemed shares. Over its last 5 closes, a net inflow of $8.4 million.
From IDNA's own holdings files. Every ETF's latest flows.
How is IDNA split by sector and country?
| Sector | Weight | Weight bar |
|---|---|---|
| Health care | 95.3% | |
| No sector found | 4.5% |
| Country | Weight | Weight bar |
|---|---|---|
| United States | 66.7% | |
| Germany | 6.2% | |
| France | 5.6% | |
| Japan | 5.2% | |
| Denmark | 5.1% | |
| Switzerland | 3.3% | |
| United Kingdom | 2.8% | |
| Canada | 2.6% | |
| Hong Kong | 1.7% | |
| Luxembourg | 0.5% | |
| Other countries | 0.2% |
From its iShares file of 2026-10-27. How these are measured.
What did IDNA hold in its SEC reports since 2019?
In IDNA's SEC filings, its largest position went from SGEN at 6.43% on 2019-10-31 to Bayer AG (BAYN.DE) at 4.81% on 2026-07-31, across 28 quarterly reports.
| Report | Positions | Largest | Top 10 |
|---|---|---|---|
| 2019-10-31 | 42 | SGEN 6.43% | 44.0% |
| 2020-10-31 | 45 | MRTX 8.30% | 45.1% |
| 2021-10-31 | 45 | MRNA 6.34% | 46.6% |
| 2022-10-31 | 38 | GMAB.DK 5.29% | 43.7% |
| 2023-10-31 | 45 | EXEL 5.73% | 46.1% |
| 2024-10-31 | 47 | EXEL 6.13% | 49.1% |
| 2025-10-31 | 44 | RVMD 4.97% | 43.9% |
| 2026-07-31 | 49 | BAYN.DE 4.81% | 43.0% |
The first report, then the last of each year, of the 28 reports IDNA filed on SEC Form N-PORT from 2019-10-31 to 2026-07-31, each company under its ticker today. Every position of every report is in its quarterly file, and at any date at /api/v1/history/idna/{date}.json. How these are read.
What does IDNA share with other ETFs?
The ETF nearest to IDNA is GNOM: the two hold 29.3% of their weight in common, in the 11 companies both own, and 33.0% of IDNA itself is also held there. No covered ETF holds more than that in common with IDNA; it duplicates nothing here closely.
| ETF | Overlap by weight | Of IDNA held there | Of that ETF in IDNA | Companies in both | Overlap bar |
|---|---|---|---|---|---|
| GNOM | 29.3% | 33.0% | 32.1% | 11 | |
| IBBQ | 22.2% | 65.7% | 28.7% | 28 | |
| IBB | 21.5% | 68.5% | 27.9% | 31 | |
| XBI | 19.3% | 57.1% | 19.5% | 25 | |
| BBH | 18.1% | 28.5% | 28.4% | 6 | |
| PBE | 17.2% | 27.1% | 21.3% | 6 | |
| CANC | 16.7% | 25.3% | 21.9% | 11 | |
| PTH | 15.4% | 19.9% | 16.1% | 6 | |
| BMED | 14.7% | 25.5% | 15.5% | 5 | |
| FBT | 14.4% | 16.2% | 14.4% | 5 | |
| IXJ | 14.1% | 47.9% | 15.7% | 12 | |
| TECB | 10.9% | 63.1% | 11.9% | 24 |
BBH's holdings are from its SEC Form N-PORT for the period ended 2026-06-30, filed 2026-08-26. CANC's holdings are from its SEC Form N-PORT for the period ended 2026-05-31, filed 2026-07-29. FBT's holdings are from its SEC Form N-PORT for the period ended 2026-06-30, filed 2026-08-21. The other ETFs' holdings are from their issuers' latest files. Check IDNA against any ETF in the ETF overlap calculator · how overlap is measured.
What adds something different to IDNA?
MCHI shares 0% of weight with IDNA and its weekly returns correlate with it at 0.29 over three years. The table lists the covered ETFs with the least in common with IDNA, least shared weight first and, among equals, lowest correlation.
| ETF | Name | Overlap by weight | Correlation, 3y | Companies in both |
|---|---|---|---|---|
| MCHI | iShares MSCI China ETF | 0.0% | 0.29 | 0 |
| SOXX | iShares Semiconductor ETF | 0.0% | 0.37 | 0 |
| RING | iShares MSCI Global Gold Miners ETF | 0.0% | 0.39 | 0 |
| PFF | iShares Preferred and Income Securities ETF | 0.0% | 0.42 | 0 |
| THRO | iShares U.S. Thematic Rotation Active ETF | 0.0% | 0.42 | 2 |
| IYR | iShares U.S. Real Estate ETF | 0.0% | 0.42 | 0 |
| USRT | iShares Core U.S. REIT ETF | 0.0% | 0.43 | 0 |
| REET | iShares Global REIT ETF | 0.0% | 0.46 | 0 |
Cost, returns and risk
| Expense ratio | 0.47% |
|---|---|
| Dividend yield | 0.66% |
| Total return, 1 year | 73.2% |
| Total return, 3 years cumulative | 131.1% |
| Total return, 5 years cumulative | -7.1% |
| Volatility, annualised | 26.2% |
| Worst fall, 3 years | -25.8% |
| Beta against SPY, 3 years of weekly returns | 0.9 |
| Weight in the ten largest positions | 49.9% |
| Largest single position | 12.2% |
| Assets under management | $0.3B |
Expense ratio, yield and assets are reference data (the expense ratio from IDNA's SEC filing of 2025-11-21); the weight in the ten largest positions and the largest single position are from the issuer file of 2026-10-27; every other figure is computed here from weekly closes.
How it moves with the market
| Against | Correlation, 3 years | Covariance, annualised, in percent squared |
|---|---|---|
| SPY | 0.48loosely linked | 173 |
| QQQ | 0.41loosely linked | 207 |
Weekly total returns. What the bands mean · why the covariance is printed.
Year by year
| Year | Total return |
|---|---|
| 2026 | 66.7% |
| 2025 | 17.3% |
| 2024 | -0.7% |
| 2023 | -7.6% |
| 2022 | -42.3% |
One year
Where to go next
- IHE, iShares U.S. Pharmaceuticals ETF
- IHF, iShares U.S. Healthcare Providers ETF
- IHI, iShares U.S. Medical Devices ETF
- IXJ, iShares Global Healthcare ETF
- Run a portfolio x-ray to see what IDNA carries once you look through it
- Compare IDNA against any other ETF in the builder
Holdings from the most recent file iShares has published, dated 2026-10-27. Prices through 2026-10-28. How every figure here is produced. Measurements, not investment advice.
Cite this page
TickerInside, iShares Genomics Immunology and Healthcare ETF (IDNA), holdings from the issuer's file of 2026-10-27, https://tickerinside.com/etf/idna/, CC BY 4.0
<a href="https://tickerinside.com/etf/idna/">TickerInside</a> (https://tickerinside.com/etf/idna/)